Technical Analysis for TILS - Tiziana Life Sciences Pl

Grade Last Price % Change Price Change
F 95.5 2.69% 2.50
TILS closed up 2.69 percent on Friday, April 16, 2021, on 1.44 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical TILS trend table...

Date Alert Name Type % Chg
Slingshot Bearish Bearish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
BB Squeeze Started Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
NR7 Range Contraction 2.69%
BB Squeeze Ended Range Expansion 2.69%
Down 3 Days in a Row Weakness 2.69%
Lower Bollinger Band Touch Weakness 2.69%
Oversold Stochastic Weakness 2.69%
Fell Below 20 DMA Bearish 0.53%
Older End-of-Day Signals for TILS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Tiziana Life Sciences Pl Description

Tiziana Life Sciences PLC is a clinical-stage biotechnology company. The Company is focused on targeted drugs to treat diseases in oncology and immunology, with a focus on metastatic cancers. Its products in clinical stage include Milciclib and Foralumab. Its products in pre-clinical stage include TZLS-101 and TZLS-214. The Company is focused on its lead compound, Milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (CDK) involved in cell division, as well as a number of other protein kinases. Milciclib is in Phase II clinical trials for thymic carcinoma. The Company's Foralumab is a fully human engineered anti-human cluster of differentiation 3 (CD3) antibody. The Company is involved in the development of Bcl-3 inhibitors. The Company's lead clinical candidate, CB1, is a Bcl-3 inhibitor with potent anti-metastatic activity.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Target Biotechnology Science Clinic Disease Life Sciences Cancer Diseases Oncology Drugs Clinical Trial Immunology Antibody Cancers Enzymes Kinase Stage Biotechnology

Is TILS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 300.0
52 Week Low 40.0
Average Volume 417,045
200-Day Moving Average 130.37
50-Day Moving Average 108.95
20-Day Moving Average 98.28
10-Day Moving Average 97.31
Average True Range 7.98
ADX 20.87
+DI 25.56
-DI 18.57
Chandelier Exit (Long, 3 ATRs ) 101.06
Chandelier Exit (Short, 3 ATRs ) 114.94
Upper Bollinger Band 104.77
Lower Bollinger Band 91.79
Percent B (%b) 0.29
BandWidth 13.20
MACD Line -3.37
MACD Signal Line -3.73
MACD Histogram 0.3629
Fundamentals Value
Market Cap 185.85 Million
Num Shares 195 Million
EPS -4.60
Price-to-Earnings (P/E) Ratio -20.76
Price-to-Sales 0.00
Price-to-Book 36.23
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 104.20
Resistance 3 (R3) 104.07 101.03 102.75
Resistance 2 (R2) 101.03 98.82 101.10 102.27
Resistance 1 (R1) 98.27 97.45 99.65 98.40 101.78
Pivot Point 95.23 95.23 95.92 95.30 95.23
Support 1 (S1) 92.47 93.02 93.85 92.60 89.22
Support 2 (S2) 89.43 91.65 89.50 88.73
Support 3 (S3) 86.67 89.43 88.25
Support 4 (S4) 86.80